1. United States Stocks

  2. •

    Health technology

  3. •

    Biotechnology
DNAPRINT GENOMICS

DNAPRINT GENOMICS

OOTC:DNAG
0.00
USD
0.00
(0.00%)
-0.01EPS
4.06MMarket Cap
DNAPRINT GENOMICS
OTC:DNAG
(OTC Markets)

Recent

price

0.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2001
2002
2003
2004
2005
2006
TTM
USD
- -
0.01
0.03
0.02
0.01
0.01
- -
Revenue per Share
-0.13
-0.14
-0.31
-0.11
-0.09
-0.03
-0.01
Basic EPS, GAAP
-0.09
-0.07
-0.06
-0.11
-0.04
-0.02
-0.01
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
0.02
-0.05
-0.08
- -
-0.04
-0.01
-0.01
Book Value per Share
0.02
-0.05
-0.08
- -
-0.05
-0.01
-0.01
Tangible Book Value per Share
20
23
25
35
94
365
546
Basic Weighted Avg Shares
- -
- -
1
1
1
2
2
Sales/Revenue/Turnover
-17,733.34
-1,416.2
-878.58
-424.42
-365.5
-364.45
-326.54
Operating Margin (%)
- -
- -
1
1
1
1
1
Depreciation Expense
-3
-3
-8
-4
-9
-12
-5
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-18,027.01
-1,687.13
-1,097.73
-475.41
-683.33
-507.54
-235.64
Profit Margin (%)
- -
-1
-2
- -
-8
-5
-9
Working Capital
- -
- -
- -
- -
- -
- -
- -
LT Debt
- -
-1
-2
- -
-4
-4
-8
Total Equity
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

USD

•

in mil. unless spec.
Mar'07
Jun'07
Sep'07
ST Debt
6
5
5
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
493
564
645
Market Capitalization
5
5
4

Working Capital

USD

•

in mil. unless spec.
Mar'07
Jun'07
Sep'07
Total Current Assets
5
4
2
Cash, Cash Equivalents & STI
5
1
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
12
12
11
Payables & Accruals
6
6
6
ST Debt
6
5
5
Deferred Revenue
- -
- -
- -

Growth Rates

USD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-947.77%
-9.28%
Free Cash Flow
- -
40.13%
65.53%
Net Income, GAAP
- -
58.64%
41.68%
Sales/Revenue/Turnover
- -
326.18%
90.75%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2005
- -
- -
- -
- -
1
2006
1
1
1
1
2
2007
1
- -
- -
- -
- -

Quarterly Earnings Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2005
-0.02
-0.04
-0.03
-0.06
-0.09
2006
-0.01
-0.01
-0.01
-0.01
-0.03
2007
0.01
- -
- -
- -
- -

Quarterly Dividends Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2005
- -
- -
- -
- -
- -
2006
- -
- -
- -
- -
- -
2007
- -
- -
- -
- -
- -
Similar Companies
Moderna, Inc. (NASDAQ:MRNA)
Amgen Inc. (NASDAQ:AMGN)
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)
Novavax, Inc. (NASDAQ:NVAX)
10x Genomics, Inc. (NASDAQ:TXG)
Business
DNAPrint Genomics, Inc. (DNAG) develops and markets genetic testing products and services focused on ancestry, forensics, and pharmacogenomics for biomedical, genealogical, consumer, and pharmaceutical clients. The company offers AncestryByDNA, a pan-chromosomal assay for genetic ancestry; EurasianDNA and EuropeanDNA for sub-continental European ancestry proportions; DNAWitness for determining genetic heritage from crime scene DNA; RETINOME for inferring physical portraits, eye color, and traits from DNA samples; and GenomeLab SNPstream Genotyping System for high-throughput SNP analysis with minimal reagents. Founded in 1983 and headquartered in Sarasota, Florida, with a subsidiary in Leverkusen, Germany, DNAPrint Genomics operates primarily in the United States and serves forensic science, genealogical research, and drug development sectors. No major acquisitions, funding rounds, partnerships, or product launches have occurred in the last 1-2 years, as the company maintains a dormant operational status following cessation of active business around 2009.

Company News

Company News APIChatGPT

  • defenseworld.net

    Head-To-Head Review: Trevi Therapeutics (NASDAQ:TRVI) vs. DNAPrint Genomics (OTCMKTS:DNAG)